See Supplemental Patient Information
- Dose-dependent and treatment-duration-dependent thyroid C-cell tumors have occurred at clinically relevant exposures in both genders of rats and mice
- Liraglutide is contraindicated in patients with a personal history or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) [US Black Box Warning]
- It is unknown whether monitoring with serum calcitonin or thyroid ultrasound will mitigate the potential risk of MTC, and such monitoring may increase the risk of unnecessary procedures, due to low test specificity for serum calcitonin and a high background incidence of thyroid disease [US Black Box Warning]
- Serious hypersensitivity reactions such as anaphylactic reactions and angioedema have been reported in patients treated with liraglutide, if such reactions develop discontinue the treatment and promptly seek medical advice. Use liraglutide cautiously in patients with a history of angioedema with another GLP-1 receptor agonist
- Acute renal failure and worsening of chronic renal failure have been reported
- Concomitant use of oral sulfonylureas increase risk of hypoglycemia
- If there is increase in serum calcitonin, the patient should be referred to an endocrinologist for further evaluation
- In clinical trials, there were more cases of pancreatitis among liraglutide treated patients than among comparator-treated patients. Observe patients carefully for signs and symptoms of pancreatitis after initiation of therapy and after dose increases, if pancreatitis is suspected, discontinue therapy. Do not restart if pancreatitis is confirmed
- Serious hypoglycemia can occur if liraglutide is used with an insulin secretagogue (e.g., sulfonylurea). Reduce dose of insulin secretagogue
- There have been no any clinical report of macrovascular risk reduction with liraglutide or any other antidiabetic drug
Cautions: Use cautiously in
- History of pancreatitis
- Gastroparesis
- Concurrent insulin
Supplemental Patient Information
- Patient should be informed that persistent severe abdominal pain, that may radiate to the back and which may (or may not) be accompanied by vomiting
- Patients should be informed to report symptoms of thyroid tumors (e.g., a lump in the neck, hoarseness, dysphagia or dyspnea) to their physician
Pregnancy Category:C
Breastfeeding: Safety unknown. As many drugs are excreted in human milk, Manufacturer recommends discontinuation of nursing or discontinuation of drug, taking into account the importance of the drug to the mother.
Pricing data from www.DrugStore.com in U.S.A.
- Victoza 18 MG/3ML SOLN [Box] (NOVO NORDISK)
9 3ml = $462.99
27 3ml = $1328 - Victoza 18 MG/3ML SOLN [Box] (NOVO NORDISK)
6 3ml = $325.98
18 3ml = $895.93
Warning: This pricing information is subject to change at the sole discretion of DS Pharmacy. For the most current and up-to-date pricing information, please visit drugstore.com.
